Previous 10 | Next 10 |
2024-06-29 15:44:55 ET More on Eli Lilly, Novo Nordisk, etc. Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Eli Lilly: Throwing Its Weight Around - But, For How Long? (Technical Analysis) Eli Lilly: The Party Is Probably Nearing The End ...
2024-06-28 09:29:56 ET More on AbbVie, Genmab, etc. AbbVie: 5 Reasons That Make A Buy Case AbbVie, Inc. (ABBV) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) AbbVie: Turnaround Lurking After The Correction Pain (Upgrade) AbbVie buys bowel...
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma PR Newswire If approved, epcoritamab (TEPKINLY ® ) will become the first and only bispecific antibody conditionally approv...
2024-06-27 14:14:36 ET Summary Top-line data from Part B of phase 3 RINGSIDE study, using AL102 for the treatment of patients with desmoid tumors, expected 2nd half of 2025. The global desmoid tumor market is projected to grow to $5.49 billion by 2032. IM-1021 is an antibody-d...
2024-06-27 14:07:44 ET More on Coherus BioSciences Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway Coherus BioSciences, Inc. (CHRS) Q1 2024 Earnings Call Transcript Coherus BioSciences Non-GAAP EPS of -$0.32 misses by $0.11, revenue of $7...
2024-06-27 14:02:20 ET More on S&P 500 Index: The Greenback Consolidates While Sustaining A Break Against The Yen Fed Update: The Fed Has A Mortgage-Backed Securities Problem Market Breadth Will Improve As The Soft Landing Comes Into View Nasdaq, S&P,...
2024-06-27 13:40:30 ET More on Cerevel Therapeutics Cerevel Therapeutics: Time For A Risk Arbitrage Play? Cerevel Therapeutics sinks amid some worry on FTC review of AbbVie deal Cerevel Therapeutics seesaws amid FTC notice on closed door meeting Seeking Alpha...
2024-06-27 11:27:19 ET Summary Immunome, Inc. stock surged over 400% post-merger and management changes but has since dropped over 60% as initial enthusiasm has waned. The company's new CEO has drawn attention to the company, which has one asset, AL102, in clinical evaluation for ...
2024-06-27 09:48:45 ET More on AbbVie AbbVie: 5 Reasons That Make A Buy Case AbbVie, Inc. (ABBV) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) AbbVie: Turnaround Lurking After The Correction Pain (Upgrade) Genmab, AbbVie win FDA nod for ...
AbbVie Acquires Celsius Therapeutics PR Newswire Celsius' CEL383 is a potential first-in-class anti-Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) antibody for the treatment of inflammatory bowel disease (IBD) NORTH CHICAGO, Ill. , June 27, ...
News, Short Squeeze, Breakout and More Instantly...
AbbVie to Host Second-Quarter 2024 Earnings Conference Call PR Newswire NORTH CHICAGO, Ill. , July 2, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2024 financial results on Thursday, July 25, 2024 , before the market opens. AbbVie wi...
2024-07-01 10:48:00 ET It's been a big year for most stocks, with the S&P 500 index up about 24% over the past 12 months. A rising market is wonderful for the stocks already in your portfolio, but finding new investment opportunities is a lot more challenging than it was a year ago....
Robert A. Michael Assumes Role as AbbVie Chief Executive Officer PR Newswire As Previously Announced, Richard A. Gonzalez Retires as Chief Executive Officer to Become Executive Chairman Robert A. Michael Joins AbbVie Board of Directors NORTH CHICAGO, Ill....